BOSTON, Dec. 15, 2014
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a
leading global biopharmaceutical services provider, today announced
that its randomization and trial supply management (RTSM) services,
ClinPhone® RTSM, ranked as the leader of Interactive Response
Technology (IRT), according to a new global survey of
pharmaceutical and biotechnology companies by Industry Standard
Research (ISR). ClinPhone RTSM was also cited as the most preferred
and widely used IRT solution.
PAREXEL Informatics' ClinPhone RTSM service has been used in
more than 3,200 studies involving more than 270,000 sites and 2.2
million patients since 1993. Additionally, ClinPhone RTSM has
been used in more than 250 studies using covariate adaptive
randomization techniques and 160 studies using adaptive trial
designs. ClinPhone RTSM is a key component of the Perceptive
MyTrials® eClinical platform, an integrated suite of applications
for managing clinical trials. PAREXEL continues to strengthen its
leadership position in RTSM. Through the recent acquisition
and integration of ClinIntel, PAREXEL's next generation ClinPhone
RTSM service offers clients an effective visual design approach
that streamlines the system delivery process. Both
ClinPhone RTSM and Perceptive MyTrials are available through the
Perceptive® Partner Program.
"ISR's report provides further endorsement of ClinPhone RTSM as
the preferred provider and leader of IRT solutions worldwide," said
Xavier Flinois, President of PAREXEL Informatics. "Randomization
and trial supply management activities are critical to the success
of our clients' clinical development journeys. Our ClinPhone RTSM
services are agile, flexible and scalable allowing us to address
the complexity of different development phases, study types,
geographic regions and client timelines."
In this report, 105 respondents rated 24 IRT vendors (including
in-house systems) across 20 different system attributes based on
user experience. Forty-eight percent of respondents rated PAREXEL
ClinPhone RTSM as the leader in the IRT field. More information
about ISR's 2014 IRT Market Dynamics and Service Provider
Benchmarking Report can be found at
www.ISRreports.com.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 81 locations in 51
countries around the world, and has approximately 15,980
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive MyTrials and ClinPhone
are trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates,"
"plans," "expects," "intends," "appears," "estimates," "projects,"
"will," "would," "could," "should," "targets," and similar
expressions are also intended to identify forward-looking
statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the recent acquisition of ClinIntel Limited, or enter
into new lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of exchange rate fluctuations and other
international economic, political, and other risks.
Such factors and others are discussed more fully in the section
entitled "Risk Factors" of the Company's Quarterly Report on Form
10-Q for the quarter ended September 30,
2014 as filed with the SEC on November 3, 2014, which "Risk Factors" discussion
is incorporated by reference in this press release. The
Company specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, Vice President,
Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-clinphone-rtsm-named-leader-of-interactive-response-technology-in-new-benchmark-report-from-industry-standard-research-300009026.html
SOURCE PAREXEL International Corporation